Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer
- 1 January 2017
- journal article
- Published by Elsevier BV in European Urology
- Vol. 71 (1), 1-3
- https://doi.org/10.1016/j.eururo.2016.07.021
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Metastatic colonization by circulating tumour cellsNature, 2016
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor CellsEuropean Urology, 2015
- RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistanceScience, 2015
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerJAMA Oncology, 2015
- Detecting predictive androgen receptor modifications in circulating prostate cancer cellsOncotarget, 2015
- Castration-Resistant Prostate Cancer: AUA Guideline AmendmentJournal of Urology, 2015
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization SignalJournal of Biological Chemistry, 2012
- Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal MarkersMolecular Cancer Research, 2011
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantJCI Insight, 2010